Key takeaways
- The dispute centers on FDA's bulk drug substance nomination process under sections 503A/503B, which governs compounding pharmacies, not RUO suppliers.
- FDA staff reviewers sort nominated peptides into categories, and 'category 2' flags insufficient data rather than proven harm.
- Most disputed peptides, including BPC-157 and thymosin beta-4 fragments, have mostly animal or lab-scale data rather than large human trials.
- PCAC panel votes weigh access and practitioner demand alongside safety data, which is why panel recommendations sometimes diverge from staff reviews.
- A supplier's certificate of analysis answers a different question than an FDA safety review, so batch-specific purity testing still matters regardless of the regulatory outcome.
In this article
The FDA doesn't always agree with itself. Right now, the agency's own staff scientists and the outside experts on its Pharmacy Compounding Advisory Committee (PCAC) are pulling in different directions on peptides. That disagreement matters for anyone paying attention to how peptides get regulated, and it says something useful about why data quality is the whole game in this field.
What the two sides are actually arguing about
Compounding pharmacies are allowed to mix custom drugs for individual patients under sections 503A and 503B of federal law. But they can only use "bulk drug substances" the FDA has cleared for that purpose. To get cleared, a substance gets nominated, then FDA staff write a review, then the PCAC (a panel of pharmacists, doctors, and public members) discusses it and votes on a recommendation.
For a growing list of peptides, FDA's staff reviewers have been sorting them into a "category 2" bucket, meaning the safety and effectiveness data on file is too thin to support compounding. The PCAC hasn't always agreed. In several recent meetings, panel members have leaned toward recommending peptides move forward anyway, weighing patient access and practitioner demand alongside the data gaps FDA staff flagged.
Why the data gap exists in the first place
Most of the peptides caught in this fight, things like BPC-157 (a synthetic 15-amino-acid chain) or thymosin beta-4 fragments, were never taken through the kind of large, controlled human trials that produce the safety and dosing data FDA usually wants. What exists instead is mostly small animal studies and lab work. That's normal for research-stage compounds. It's also exactly why FDA staff keep writing "insufficient data" instead of "safe" or "unsafe." Insufficient data is not the same as a red flag on the molecule itself. It just means nobody has done the expensive human studies yet.
This is the same gap researchers run into at the bench. A compound can behave predictably in a test tube and still have open questions about stability, degradation byproducts, and batch-to-batch consistency once it leaves a controlled study.
Where FDA staff and the panel diverge
What the research community gets wrong about this fight
- This dispute is about the human compounding pathway (503A/503B pharmacies), not about research-use-only peptides purchased for bench work. It doesn't change how RUO material is sold or labeled.
- A "category 2, insufficient data" label from FDA staff is not a finding that a peptide is dangerous. It's a statement that the evidence bar for compounding hasn't been cleared yet.
- PCAC votes are recommendations, not rules. FDA can and sometimes does go a different direction than the panel.
- None of this substitutes for a certificate of analysis on the material sitting in your freezer. The FDA review process and a supplier's HPLC or mass spec purity report are answering completely different questions.
- A long history of a peptide being used somewhere is not the same as documented stability or degradation data for the specific batch and diluent you're working with.
The bench takeaway
Whatever FDA and its panel eventually decide about compounding, the underlying issue they're arguing over, thin data on stability, purity, and behavior over time, is the same issue that should shape how you handle peptides at the bench. Reconstitute with bacteriostatic water stored cold and used within its labeled window. Keep reconstituted vials refrigerated and shielded from light. Ask suppliers for a batch-specific certificate of analysis, not a generic spec sheet. The regulatory fight is a reminder that "we don't have enough data" is a common state for this whole class of molecules, so your own documentation and storage discipline are what actually protect a sample's integrity.
Frequently asked questions
Does the FDA peptide compounding dispute affect research-use-only peptides?
No. The disagreement is about pharmacies compounding peptides for human patients under FDA rules. RUO peptides sold for lab research fall outside that specific pathway.
What does FDA's 'category 2' label mean for a peptide?
It means FDA staff reviewers found the safety and effectiveness data on file insufficient to support compounding, not that the substance has been shown to be harmful.
Is a Pharmacy Compounding Advisory Committee vote binding on the FDA?
No. The PCAC gives a recommendation. FDA staff and leadership make the final call and can diverge from the panel's vote.
Prompted by this coverage at Google News →
Sources
- Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
- Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
- Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
✔ Reviewed by Bryan Le, PharmD, RPh
Bryan is a licensed pharmacist (Doctor of Pharmacy, Registered Pharmacist). Reconstituting lyophilized preparations is core pharmacy practice, so he reviews The Lab’s content for technical accuracy and to keep it within a research-and-education scope, with no medical or dosing advice. View profile on LinkedIn.
Related from our lab: the pen · cartridges · bacteriostatic water · reconstitution calculators
Shared by PreppinPeppers for research, educational, and demonstration awareness only. We link to third-party coverage; we do not endorse it, and nothing here is medical advice or a recommendation to use any substance in humans or animals. Our products are sold for laboratory research use only.
